Skip over navigation

Events and Seminars

All seminars are held in the Edward C. Taylor Auditorium in the Frick Chemistry Laboratory unless otherwise noted.  Please contact the chemistry front office at (609) 258-3900 if you require special assistance to attend any lecture. Assistive listening devices are available upon request.

9/5 - Eli Lilly Seminar: Richard Gaynor, MD, Eli Lilly and Co.

Richard Gaynor, MD
Senior Vice President
Global Oncology Development and Medical Affairs
Eli Lilly and Co. - company website


Development of Alimta for the Tailored Treatment of Lung Cancer


Richard B. Gaynor, M.D. joined Eli Lilly and Company in August 2002 and is currently Senior Vice President, Oncology Product Development and Medical Affairs.


Gaynor received a doctor of medicine degree from the University Of Texas Southwestern Medical School. He served his internship and residency in internal medicine from at Parkland Memorial Hospital in Dallas, Texas. He completed a fellowship in hematology-oncology at the University of California at Los Angeles (UCLA) School of Medicine and then served on the faculty there. He received board certification in internal medicine, hematology and medical oncology.


Prior to joining Lilly, Gaynor was a Professor of Medicine and Microbiology at the University of Texas Southwestern Medical Center (UTSW) in Dallas and held several important leadership positions. He was Chief of the Division of Hematology and Oncology at UTSW and Director of the Harold C. Simmons Comprehensive Cancer Center there in addition to his work as the Lisa K. Simmons Distinguished Chair in Comprehensive Oncology. He served on numerous NIH advisory committees and was elected to both the American Society of Clinical Investigation and Association of American Physicians.


Gaynor is on the editorial board of several scientific journals and has an extensive publication record totaling more than 140 scientific articles. He serves on the board of the Damon Runyon Cancer Research Foundation and the Walther Cancer Institute and on several committees for the American Association of Cancer Research and other leading cancer organizations.